Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 9,265 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: GVHD, Acute Clear all

Conditions: Sickle Cell Disease
Interventions: ICA-17043; Drug
Lead sponsor: Icagen; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 42
States / cities: Mobile, Alabama • Little Rock, Arkansas • Davis, California + 39 more

Conditions: End-stage Renal Disease, Malnutrition; Protein
Interventions: Intradialytic Parenteral Nutrition; Other
Lead sponsor: Patient Care America; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Pompano Beach, Florida

Conditions: Hematologic Malignancy, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Lymphoma, Leukemia, Myeloma
Interventions: Transfusion support; Other
Lead sponsor: Adam Olszewski; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Acute Myeloid Leukemia
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy Volunteers
Interventions: Placebo, MEDI5884 Dose 1, MEDI5884 Dose 2, MEDI5884 Dose 3, MEDI5884 Dose 4; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Glendale, California

Conditions: Acute Renal Failure
Interventions: Selective cytopheretic device (SCD); Device
Lead sponsor: SeaStar Medical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 4 more

Conditions: Acute Respiratory Failure, Airway Extubation
Interventions: Traditional online education, Interprofessional education, Clinical protocol, Risk-stratified preventive post-extubation noninvasive ventilation (NIV) or high-flow nasal cannula oxygen (HFNC), Preventive post-extubation high-flow nasal cannula oxygen (HFNC); Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 12,857 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 17
States / cities: Carlisle, Pennsylvania • Hanover, Pennsylvania • Harrisburg, Pennsylvania + 7 more

Conditions: Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Acute Promyelocytic Leukemia (M3), Recurrent Adult Acute Myeloid Leukemia, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: vorinostat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Palliative Care, Standard Leukemia care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Columbus, Ohio

Conditions: Taste Sweet, Taste Salty, Feeding Behavior
Interventions: taste acuity assessment, Recorded meal; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myeloid Leukemia
Interventions: Not listed
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acute Myeloid Leukemia, AML
Interventions: XL999; Drug
Lead sponsor: Symphony Evolution, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Alhambra, California • Los Angeles, California • Northridge, California + 3 more

Conditions: Relapsed Acute Myeloid Leukemia
Interventions: Imetelstat, Azacitidine, Venetoclax; Drug
Lead sponsor: Douglas Tremblay; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: New York, New York

Conditions: Kawasaki Disease
Interventions: Infliximab, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 4 Weeks to 17 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: La Jolla, California • Columbus, Ohio

Conditions: Acute Myeloid Leukemia, Lymphoblastic Leukemia, Acute Leukemia, Non Hodgkins Lymphoma, Chronic Myeloid Leukemia
Interventions: IM-TMI (3Gy), IM-TMI (6Gy), IM-TMI (9Gy), IM-TMI (12Gy); Radiation
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Lymphoblastic Leukemia
Interventions: Ibrutinib, Dasatinib, Prednisone; Drug
Lead sponsor: University of Utah; Other
Eligibility: 60 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
Interventions: Sirolimus; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Heart Transplant Failure and Rejection, Heart Failure, Heart Diseases, Heart Failure，Congestive, Transplant; Failure, Heart, Transplant Failure
Interventions: Not listed
Lead sponsor: University of British Columbia; Other
Eligibility: 19 Years and older
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Interventions: Clofarabine; Drug
Lead sponsor: New York Medical College; Other
Eligibility: Up to 30 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Vallhala, New York

Conditions: Migraine
Interventions: Dexamethasone 4mg, Dexamethasone 16mg; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Acute Kidney Injury
Interventions: Conventional Foley Catheter(Medline), Accuryn Foley Catheter; Device
Lead sponsor: Dang Tan Phat; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Irvine, California

Conditions: Acute Respiratory Failure
Interventions: Early ICU rehabilitation strategies, Usual Care; Other
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Acute Myeloid Leukemia, Hematologic Malignancy, Bone Marrow Transplantation
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 4 Years to 21 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Post-COVID-19 Syndrome, Postural Tachycardia Syndrome, Dysautonomia
Interventions: Non-invasive vagus nerve stimulation, Sham Intervention; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Stratified Sickle Event Randomized Trial (ASSERT)

Impact of IDPN on Nutrition Markers in Patients Receiving ICHD

Removing Transfusion Dependence as a Barrier to Hospice Enrollment

Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure

The Maximizing Extubation Outcomes Through Educational and Organizational Research (METEOR) Trial

Vorinostat in Treating Patients With Acute Myeloid Leukemia

A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy

Taste Acuity and Caloric Intake After Acute Morphine Administration

Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients

Study of XL999 in Patients With Acute Myeloid Leukemia (AML)

Imetelstat Combinations in Relapsed AML

Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease

Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies

Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection

Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL

Dexamethasone for Migraine - Dose Comparison

Intraabdominal Pressure Monitoring Urinary Catheter and Kidney Perfusion Pressure

Effect Of Acute Inflammatory Mediators On Functional Limitations In Patients With Acute Respiratory Failure

The Oronasal Microbiota in Pediatric Oncology Patients

VNS for Long-COVID-19